|1.||Goldberg, Richard M: 37 articles (04/2015 - 01/2002)|
|2.||Ohtsu, Atsushi: 32 articles (10/2015 - 01/2002)|
|3.||Friedman, Henry S: 28 articles (07/2015 - 04/2002)|
|4.||Yamada, Yasuhide: 27 articles (10/2015 - 01/2002)|
|5.||Shirao, Kuniaki: 27 articles (04/2014 - 01/2002)|
|6.||Georgoulias, V: 27 articles (12/2012 - 06/2000)|
|7.||Falcone, Alfredo: 26 articles (10/2015 - 04/2002)|
|8.||Boku, Narikazu: 26 articles (10/2015 - 01/2003)|
|9.||Saijo, Nagahiro: 26 articles (04/2014 - 01/2002)|
|10.||Kim, Tae Won: 25 articles (05/2015 - 12/2004)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
11/21/2015 - "After irinotecan was introduced for the treatment of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. "
11/01/2001 - "Weekly CPT-11/5-FU/FA is highly effective in the treatment of patients with metastatic colorectal cancer limited to the liver, even after failure of previous 5-FU/FA. "
01/01/2010 - "To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer. "
08/01/2000 - "Thus, considering other encouraging data from the literature, the CPT-11 + FU-LV combination therapy can be regarded as a new, very effective treatment option for first-line treatment of advanced colorectal cancer patients."
01/01/2008 - "This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer. "
08/16/2004 - "The role of the UGT1A1 genotype as a predictor of toxicity in cancer patients receiving irinotecan demands the performance of a randomized trial to ascertain whether genotype-adjusted dosages of the drug can help to establish safe and effective doses not only for patients with the UGT1A1(*)28 homozygous genotype but also for those with the most common UGT1A1 6/6 or 6/7 genotype."
03/01/2007 - "The chemotherapeutic agent irinotecan (IT) is highly effective against several types of cancer, although its use is limited due to severe intestinal toxicity. "
12/01/2014 - "Etirinotecan pegol was eliminated very slowly from the tumor (t 1/2 = 17 days), achieving higher and more sustained tumor exposure when compared with conventional irinotecan. "
04/01/2004 - "HACE with irinotecan induced a complete remission in 44% of the animals and the highest dose reduced the mean tumor cell load by 66% (P < 0.001). "
01/02/2015 - "These nanoassemblies maintain a high (∼47 %) drug loading and exhibit greater drug stability (i.e., resistance to lactone hydrolysis), and consequently greater efficacy against several human cancer cells (HT-29, A549, H460, and H23) in vitro compared with the clinically used prodrug irinotecan. "
|3.||Neoplasm Metastasis (Metastasis)
10/01/2010 - "NK012 eradicated the liver metastases and produced a significant longer survival rate than CPT-11 (P = 0.0006). "
11/01/2007 - "HAI (WHF: 1000 mg/m2) plus CPT-11 (100 mg/m2) was effective, and liver metastases showed a significant reduction (PR) on abdominal CT. "
03/01/2003 - "Combination therapy of FR-WBH + CPT-11 resulted in a significantly greater inhibition of axillary lymph node metastasis volume compared to both control and CPT-11 alone (p < 0.02) at day 16. "
11/01/2007 - "HAI plus CPT-11 was effective for a patient of the poor performance status with unresectable liver metastasis."
04/01/2015 - "To compare the feasibility, safety, and efficacy with small and large irinotecan drug-eluting beads (DEBIRI) for treating hepatic colorectal metastases. "
|4.||Stomach Neoplasms (Stomach Cancer)
06/01/2007 - "CPT-11 appeared to be highly efficacious when given in combination with CDDP in human gastric cancer cell lines. "
03/01/2011 - "Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment."
01/15/2013 - "Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials."
12/01/2007 - "The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated and effective in patients with advanced gastric cancer. "
09/01/2005 - "S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer."
|5.||Colonic Neoplasms (Colon Cancer)
03/01/2004 - "This case suggests the efficacy of home anticancer therapy with PMC and low-dose CPT-11 for highly advanced colon cancer in terms of QOL."
07/01/2009 - "CONCLUSION Irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival in patients with stage III colon cancer compared with LV5FU2 alone."
08/20/2008 - "The efficacy of NGO-PEG-SN38 was far higher than that of irinotecan (CPT-11), a FDA-approved water soluble SN38 prodrug used for the treatment of colon cancer. "
06/01/2005 - "Therefore, CRAd-sCE2/CPT-11 combination therapy appears useful for more effective treatment of colon cancer."
08/01/2004 - "l-LV/5-FU/low-dose CPT-11 seems to be effective for metastatic colon cancer, and safe from the toxicity standpoint."
|3.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)